Our objective was to develop a population pharmacokinetic (PK) model in order to evaluate the currently recommended dosing regimen in term and preterm neonates. By using an optimal design approach, a prospective PK study was designed and implemented in 60 neonates with postmenstrual ages (PMA) of 26 to 43 weeks. A loading dose of 16 mg/kg was administered at day 1, followed by a maintenance dose of 8 mg/kg daily. Plasma concentrations were quantified by high-pressure liquid chromatography–mass spectrometry. Population PK (popPK) analysis was performed using NONMEM software. Monte-Carlo (MC) simulations were performed to evaluate currently recommended dosing based on a pharmacodynamic index of area under the concentration-time curve (AUC)/MI...
AIM: This study aims to investigate the clinical and demographic factors influencing gentamicin phar...
Imipenem is a broad-spectrum antibacterial agent used in critically ill neonates after failure of fi...
Sepsis remains a major cause of mortality and morbidity in neonates, and, as a consequence, antibiot...
There is uncertainty about the optimal teicoplanin regimens for neonates. The study aim was to deter...
Teicoplanin is frequently administered to treat Gram-positive infections in pediatric patients. Howe...
The aim of this study was to develop a population pharmacokinetic (PK) model for teicoplanin across ...
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't. This trial has been registered in...
Background and Objectives: Teicoplanin is a highly protein-bound antibiotic, increasingly used to tr...
International audienceObjectives: To investigate the population pharmacokinetics of teicoplanin in p...
Background and Objectives Teicoplanin is a highly protein-bound antibiotic, increasingly used to tre...
Objective: Imipenem is a broad spectrum antibiotic used to treat severe infections in critically ill...
The long elimination half-life of teicoplanin facilitates outpatient parenteral antibiotic therapy (...
Paediatric patients, particularly preterm neonates, present many pharmacological challenges. Due to ...
AIM: This study aims to investigate the clinical and demographic factors influencing gentamicin phar...
Imipenem is a broad-spectrum antibacterial agent used in critically ill neonates after failure of fi...
Sepsis remains a major cause of mortality and morbidity in neonates, and, as a consequence, antibiot...
There is uncertainty about the optimal teicoplanin regimens for neonates. The study aim was to deter...
Teicoplanin is frequently administered to treat Gram-positive infections in pediatric patients. Howe...
The aim of this study was to develop a population pharmacokinetic (PK) model for teicoplanin across ...
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't. This trial has been registered in...
Background and Objectives: Teicoplanin is a highly protein-bound antibiotic, increasingly used to tr...
International audienceObjectives: To investigate the population pharmacokinetics of teicoplanin in p...
Background and Objectives Teicoplanin is a highly protein-bound antibiotic, increasingly used to tre...
Objective: Imipenem is a broad spectrum antibiotic used to treat severe infections in critically ill...
The long elimination half-life of teicoplanin facilitates outpatient parenteral antibiotic therapy (...
Paediatric patients, particularly preterm neonates, present many pharmacological challenges. Due to ...
AIM: This study aims to investigate the clinical and demographic factors influencing gentamicin phar...
Imipenem is a broad-spectrum antibacterial agent used in critically ill neonates after failure of fi...
Sepsis remains a major cause of mortality and morbidity in neonates, and, as a consequence, antibiot...